Results 1 to 10 of about 5,982 (143)

GLP-1RA and the possible skin aging. [PDF]

Endocrine
Abstract “Ozempic face” and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic inflammation and possibly promote skin health.
Paschou IA, Sali E, Paschou SA, Tsamis KI, Peppa M, Psaltopoulou T, Nicolaidou E, Stratigos AJ.   +7 more
europepmc   +3 more sources

GLP-1RA Use and Thyroid Cancer Risk.

JAMA Otolaryngol Head Neck Surg
ImportanceThe increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RA) demands a better understanding of their association with thyroid cancer.ObjectiveTo estimate the risk of incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1RA vs other common glucose-lowering medications.Design, Setting, and ...
Brito JP, Herrin J, Swarna KS, Singh Ospina NM, Montori VM, Toro-Tobon D, Umpierrez GE, Galindo RJ, Deng Y, Mickelson MM, Shao H, Polley EC, McCoy RG.   +12 more
europepmc   +3 more sources

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD [PDF]

Kidney International Reports
Introduction: Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of
Ajay K. Singh, Stefan D. Anker, Bertram Pitt, Peter Rossing, Luis M. Ruilope, Christiane Ahlers, Youssef M.K. Farag, Marc Lambelet, Meike D. Brinker, Katja Rohwedder, Gerasimos Filippatos   +10 more
doaj   +2 more sources

The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review. [PDF]

J Eur Acad Dermatol Venereol
Abstract Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP‐1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and cardiovascular risk reduction.
Paschou IA, Sali E, Paschou SA, Psaltopoulou T, Nicolaidou E, Stratigos AJ.   +5 more
europepmc   +4 more sources

GLP-1RA Medications Significantly Reduce Fracture Risk in the Diabetic Foot and Ankle Patient Population [PDF]

Foot & Ankle Orthopaedics
Research Type: Level 3 - Retrospective cohort study, Case-control study, Meta-analysis of Level 3 studies Introduction/Purpose: Diabetes mellitus (DM) is associated with an elevated risk for sustaining a fracture, driven by both direct and indirect ...
Samantha Olson BS, Alexandra Vaughan-Masamitsu BS, Michael Levidy MD, Lincoln Dutcher MD, Jana Davis MD   +4 more
doaj   +2 more sources

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS

Frontiers in Pharmacology, 2022
Background: GLP-1 receptor agonists (GLP-1RA) have demonstrated cardiovascular benefits, but the relationship between GLP-1RA and tumors is controversial.
Zheng Yang, Yuhuan Lv, Meng Yu, Mei Mei, Linyu Xiang, Subei Zhao, Rong Li   +6 more
doaj   +1 more source

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United StatesPlain-Language Summary

Kidney Medicine, 2023
Rationale & Objective: Information regarding disparities in initiating sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) in patients with chronic kidney disease (CKD) is limited.
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
doaj   +1 more source

The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study [PDF]

Diabetes & Metabolism Journal, 2023
We compared the glycemic efficacy of treatment intensification between quadruple oral antidiabetic drug therapy and once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA)-based triple therapy in patients with poorly controlled type 2 diabetes ...
Minyoung Kim, Hosu Kim, Kyong Young Kim, Soo Kyoung Kim, Junghwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Jong Ha Baek   +7 more
doaj   +1 more source

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany. [PDF]

PLoS ONE, 2016
AIMS:To investigate real-world clinical and patient-related variables associated with initiating GLP-1 receptor agonist (GLP-1RA) treatment relative to initiation of other glucose-lowering therapies in type 2 diabetes (T2D) patients of primary care in ...
Qing Qiao, Susan Grandy, Josh Hiller, Karel Kostev   +3 more
doaj   +1 more source

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies

Metabolites, 2022
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits.
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino   +6 more
doaj   +1 more source